Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

Clinical Cancer Research

Volumn 13, Issue 10, 2007, Pages 2986-2991

  Ekeblad, Sara ^a   Sundin, Anders ^a   Janson, Eva Tiensuu ^a   Welin, Staffan ^a   Granberg, Dan ^a   Kindmark, Henrik ^a   Dunder, Kristina ^a   Kozlovacki, Gordana ^a   Örlefors, Håkan ^a   Sigurd, Mattias ^a   Öberg, Kjell ^a   Eriksson, Barbro ^a   Skogseid, Britt ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASCITES; BRONCHUS CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; ENDOCRINE DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPOCALCEMIA; IMAGING SYSTEM; LEUKOPENIA; LOW BACK PAIN; LUNG EMBOLISM; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYCOPLASMA PNEUMONIA; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS TUMOR; PARAGANGLIOMA; PLEURA EFFUSION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SEIZURE; SIDE EFFECT; STOMACH CANCER; STOMACH PAIN; THROMBOCYTOPENIA; THYMUS CANCER; WEIGHT REDUCTION;

AGED; BRONCHIAL NEOPLASMS; CARCINOID TUMOR; DACARBAZINE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34249818466     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2053     Document Type: Article

References (18)

1. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
2. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006;106:175-65.
3. Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol 2005;53:241-52.
4. Bajetta E, Rimassa L, Carnaghi C, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998; 83:372-8.
5. Bajetta E, Ferrari L, Procopio G, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002;13:614-21.
6. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-93.
7. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-6.
8. IsacoffWH, Moss RA, Pecora AL, Fine RL. Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings, part I vol. 24, No. 18S (June 20 Supplement).
9. Kulke MHSK, Earle CC. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings, part I, vol. 24, No. 18S (June 20 Supplement).
10. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4.
11. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
12. House MG, Herman JG, Guo MZ, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003;238: 423-31; discussion 31-2.
13. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003;22:924-34.
14. Tsuchida Y, Therasse P. Response Evaluation Criteria in Solid Tumors (RECIST): new guidelines. Med Pediatr Oncol 2001;37:1-3.
15. Stridsberg M, Hellman U, Wilander E, Lundqvist G, Hellsing K, Oberg K. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993;139:329-37.
16. Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001;12:1383-91.
17. Gal AA, Kornstein MJ, Cohen C, Duarte IG, Miller JI, Mansour KA. Neuroendocrine tumors of the thymus: a clinicopathological and prognostic study. Ann Thorac Surg 2001;72:1179-82.
18. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22:610-6.